Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures rarely read like light fiction. Tenax Therapeutics’ SEC documents splice dense trial statistics, cash-burn tables and patent language into hundreds of pages that can leave even seasoned analysts searching for answers. Whether you’re tracing Phase 3 levosimendan milestones or gauging dilution risk, you need clarity fast. Stock Titan delivers Tenax Therapeutics SEC filings explained simply with objective, machine-learned context.
Open any Tenax Therapeutics annual report 10-K simplified and our AI-powered highlights surface key risk factors, R&D spend and going-concern notes in seconds. The same engine breaks down each Tenax Therapeutics quarterly earnings report 10-Q filing, flags shifts in cash runway and links management commentary to actual numbers. Real-time alerts push Tenax Therapeutics Form 4 insider transactions real-time to your dashboard, so following Tenax Therapeutics executive stock transactions Form 4 around pivotal study announcements feels effortless. Need the story behind sudden market moves? Our summary cards turn every Tenax Therapeutics 8-K material events explained into a two-minute brief.
- Compare R&D spending trends to gauge Phase 3 financing health.
- Catch Tenax Therapeutics insider trading Form 4 transactions before traditional news feeds refresh.
- Review Tenax Therapeutics proxy statement executive compensation to see how incentives align with trial endpoints.
- Dive into catalyst timelines through understanding Tenax Therapeutics SEC documents with AI.
- Export models built from Tenax Therapeutics earnings report filing analysis without combing through footnotes.
Every document arrives within minutes of posting to EDGAR, already tagged with plain-English summaries and searchable data points. Stop juggling PDFs; let our AI surface the insights that shape Tenax Therapeutics’ future.
Tenax Therapeutics, Inc. (TENX)11/18/2025, the insider purchased 1,612 shares at a weighted average price of
The filing also lists existing stock options held by the insider. These include options exercisable for 157 shares of common stock expiring on
Tenax Therapeutics, Inc. (TENX) director reported open-market purchases of common stock and corrected how those shares are reported. On 11/17/2025, an indirect account bought 93 shares at $7.15 per share, and on 11/18/2025 it bought 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 shares held through Meadowlark Management, LLC. This amended Form 4 changes the ownership form for those 1,993 shares from direct to indirect, clarifying that the director disclaims beneficial ownership beyond her economic interest.
Tenax Therapeutics (TENX)11/17/2025, the officer bought 2,000 shares of common stock directly and now holds 2,000 shares in their own name. On the same date, they reported additional purchases of 1,000 shares held indirectly through a child and 5,000 shares held indirectly through a spouse.
The direct shares were acquired at a weighted average price of $7.337, with trades executed between $7.14 and $7.43. The spouse’s shares were bought at a weighted average price of $7.228, with trades between $7.17 and $7.30, and the child’s shares at $7.35. All transactions were coded as open-market purchases.
Tenax Therapeutics, Inc. (TENX) director reports open‑market share purchases. A company director filed a Form 4 disclosing two common stock purchases on 11/17/2025 and 11/18/2025. The director bought 93 shares at $7.15 per share and another 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 common shares held directly after these trades. The filing also lists stock options giving the right to buy Tenax common stock, including 100,000 options at an exercise price of $5.94 exercisable from 12/10/2025 to 12/10/2034, and 80,000 options at an exercise price of $5.75 exercisable from 07/01/2026 to 07/01/2035, along with two smaller legacy option grants of 4 shares each.
Tenax Therapeutics (TENX) reported Q3 2025 results with a net loss of $15.8 million as it advanced Phase 3 programs. Operating expenses were $16.8 million, driven by research and development of $10.3 million and general and administrative of $6.5 million. Interest income was $1.0 million.
Liquidity remained strong with cash and cash equivalents of $99.4 million and working capital of $96.2 million as of September 30, 2025. Shares outstanding were 5,907,233 as of September 30, 2025; 6,243,575 were outstanding as of November 11, 2025. The company closed a March 2025 private placement for gross proceeds of $25.0 million.
Program and licensing updates: Tenax continues enrolling the Phase 3 LEVEL study and plans a second global Phase 3 (LEVEL‑2). A September 3, 2025 amendment with Orion expanded exclusive worldwide rights to orally administered levosimendan and set API supply terms. Prior amendments include a
Tenax Therapeutics (TENX)Exhibit 99.1 and, as noted under Item 2.02, is not deemed “filed” for purposes of Section 18 of the Exchange Act. The company’s common stock trades on Nasdaq under the symbol TENX.
Tenax Therapeutics (TENX) disclosed that Ikarian Capital, LLC and Neil Shahrestani together report beneficial ownership of 967,600 shares of common stock, representing 21.2% of the outstanding class based on 4,562,500 shares outstanding. The reported position reflects shared voting and shared dispositive power over the 967,600 shares rather than sole control.
The holdings are held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts for which Ikarian Capital acts as adviser; Mr. Shahrestani is identified as the ultimate controller of Ikarian Capital. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Tenax Therapeutics received a Schedule 13G disclosing that affiliated investment vehicles controlled by Raymond Debbane hold meaningful common stock positions. Invus Public Equities directly holds 366,143 shares, reported as 8.0% of the class, and Avicenna Life Sci Master Fund directly holds 60,998 shares, reported as 1.3%. Collectively, Mr. Debbane is reported as the beneficial owner of 427,141 shares, or 9.4%, based on an outstanding share count of 4,562,500 as reported by the issuer. The filing states these positions are not held to change or influence control of the company.
FAQ
What is the current stock price of Tenax Therapeutics (TENX)?
What is the market cap of Tenax Therapeutics (TENX)?
